Premium
Quantitation of dexfenflurainine/d‐norfenfluramine concentration in primate brain using 19 F NMR spectroscopy
Author(s) -
Christensen James D.,
Babb Suzann M.,
Cohen Bruce M.,
Renshaw Perry F.
Publication year - 1998
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1910390121
Subject(s) - metabolite , chemistry , in vivo , active metabolite , nuclear magnetic resonance spectroscopy , human brain , chromatography , nuclear magnetic resonance , biochemistry , stereochemistry , medicine , biology , physics , psychiatry , microbiology and biotechnology
Fluorine ( 19 F) magnetic resonance spectroscopy (MRS) was used to quantify the combined concentration of the anorectic drug dexfenfluramine (DF) and its active metabolite d‐norfenfluramine (dNF) in rhesus monkey brain. The accuracy of the MRS technique was assessed by comparison with gas chromatography. Brain 19 F MRS signals were converted to brain DF + dNF concentrations after correction for signal relaxation losses and drug distribution in nonbrain tissue. Gas chromatography (GC) was used to assay brain DF and dNF concentrations following MRS evaluation. DF + dNF concentrations measured by 19 F MRS averaged 104 ± 36 μM (mean ± SD) and GC measurements averaged 71 ± 12 μM. Correction for the distribution of DF and its metabolites in nonbrain tissue yielded a DF + metabolite brain concentration that was within one standard deviation of the GC‐derived value. The concentration of DF plus dNF measured by 19 F MRS was similar to or greater than the value obtained by GC, which indicates that DF and its active metabolite dNF are fully detected by 19 F MRS in primate brain in vivo. The application of these techniques to human subjects should enable the measurement of low micromolar‐range brain concentrations of DF and other fluorinated drugs.